P52 Immune-mediated diabetes secondary to the use of immune checkpoint inhibitors

Abstract

Introduction: The use of immune check point inhibitors (ICIs) modified the focus of cancer therapy. ICIs are monoclonal auto-antibodies directed against inhibitory T cell receptors (immune checkpoints), which act as negative co-regulators to limit immune activation. Adverse events related to the endocrine system (irAE) are observed between 4-30%. Immune-mediated diabetes mellitus (DM) is the least frequent complication (less than 1%) but is potentially fatal. Objectives: To describe the characteristics and frequency of immune-mediated DM in patients with ICIs. Materials and methods: Retrospective, descriptive, observational study. It included patients of both genders older than 18 years in treatment with ICIs from 2018 to date. Hormone profile and fasting plasma glucose were requested in basal conditions and prior to each infusion. Categorical variables are expressed as a percentage and continuous variables, as median and intercuratil range (IQR).

Keywords

• diabetes inmunomediada
• inhibidores de los checkpoint inmune